OGI
Organigram Global Inc
NASDAQ · Pharmaceuticals
$1.53
+0.05 (+3.38%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 80.01M | 81.33M | 78.64M |
| Net Income | 10.95M | 15.27M | 12.59M |
| EPS | — | — | — |
| Profit Margin | 13.7% | 18.8% | 16.0% |
| Rev Growth | -6.4% | -3.5% | +20.8% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 29.25M | 25.95M | 29.36M |
| Total Equity | 141.96M | 132.90M | 143.87M |
| D/E Ratio | 0.21 | 0.20 | 0.20 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 20.99M | 21.57M | 20.37M |
| Free Cash Flow | 12.68M | 16.42M | 10.74M |